Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - A double-blind, placebo-controlled clinical trial

Spinal Cord

Volumn 37, Issue 3, 1999, Pages 196-200

  Stohrer M ^a   Madersbacher, H ^d   Richter, R ^e   Wehnert, J ^b   Dreikorn, K ^c  

^a BG UNFALLKLINIK MURNAU   (Germany)

^b Urologist   (Germany)

^c Department of Pediatric Surgery   (Germany)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^e NONE

Author keywords

Detrusor hyperreflexia; Propiverine; Spinal cord injury; Urodynamics

Indexed keywords

PROPIVERINE; URINARY TRACT SPASMOLYTIC AGENT;

ACCOMMODATION; ADULT; ARTICLE; BLADDER; BLADDER CAPACITY; BLADDER CATHETERIZATION; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERREFLEXIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CONTRACTION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SPINAL CORD INJURY; URODYNAMICS; VERTIGO; XEROSTOMIA;

EID: 0032984844     PISSN: 13624393     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.sc.3100750     Document Type: Article

References (16)

1. 1 Alloussi S et al. Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder. Investigative Urology 1991; 4: 157-161.
2. 2 Riotte J, Mutschler E. Untersuchungen zur spasmolytischen Aktivität von Propiverin und cinigen seiner Strukturanaloga. Arzneimittel-Forsch 1987; 37: 300-302.
3. 3 Wada Y et al. Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn 1995; 330: 76-89.
4. 4 Halaska M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics 1994; 13: 428-430.
5. 5 Mazur D et al. Klinische und urodynamische Effekte einer oralen Propiverintherapie bei neurogener Harninkontinenz. Urologe [A] 1994; 33: 447-452.
6. R ) eine randomisierte Cross-over-Vergleichsstudie. Akt Urol 1992; 23: 7-11.
7. 7 Mazur D et al. Verträglichkeit und Wirksamkeit einer Langzeittherapie mit Propiverinhydrochlorid bei neurogener Harninkontinenz Eine multizentrische Studie. Kontinenz 1994; 3: 74-78.
8. 8 Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardization of terminology of lower urinary tract function. Br J Obstet Gynaecol 1990; 97: suppl. 6, pp 1-16.
9. 9 Knoll M, Madersbacher H. The chances of a spina bifida patient becoming continent/socially dry by conservative therapy. Paraplegia 1993; 31: 22-27.
10. 10 Yokota T, Yamaguchi O. Changes in cholinergic and purinergic neurotransmission in pathologic bladder of chronic spinal rabbit. J Urol 1996; 156: 1862-1866.
11. R tablet 10.20). Unpublished report February 1997.
12. 12 Madersbacher H et al. Trospium chloride versus oxybutinin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 1995; 75: 452-456.
13. 13 Thüroff JW et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-817.
14. 14 Madersbacher H el al. Tolerability and efficacy of propiverine hydrochloride in patients with urge incontinence in comparison to oxybutynin and placebo a urodynamically controlled multicenler study. Br J Urol 1998; submitted.
15. 15 Meisel P, Langner S, Siegmund W. In-vitro binding of propiverine hydrochloride and some of its metabolites to scrum albumin in man. J Pharmacy a Pharmacol 1997; 33: 270-272.
16. 16 Potthast H, Schug B, Blume H. Bioavailability study of Mictonorm Dragees (Apogepha Arzneimittel GmbH) after single dose administration in comparison to multiple dose administration. Unpublished report, 1996.